Goldman SachsGSTOP PICKJan 28, 2021Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Stockchase Research Editor: Michael O'Reilly GS is a world leader in investment banking and wealth management services. It has global diversification and is ideally situated for an evitable rebound in IPO and M&A activity. Recent earnings showed a 22% increase in revenues over the year and EPS that beat analyst expectations. It trades at 12x earnings, compared to 21x for its peers. It pays a decent yield, backed by a payout ratio of under 40% of cashflow. We would buy this with a stop-loss at $225, looking to achieve $327 -- over 16% upside. Yield 1.83% (Analysts’ price target is $327.06)